JNJ

235.52

+0.87%↑

ISRG

477.08

-0.52%↓

ABT

109.53

+0.63%↑

RDY

13.98

+1.3%↑

NEOG

10.33

+0.68%↑

JNJ

235.52

+0.87%↑

ISRG

477.08

-0.52%↓

ABT

109.53

+0.63%↑

RDY

13.98

+1.3%↑

NEOG

10.33

+0.68%↑

JNJ

235.52

+0.87%↑

ISRG

477.08

-0.52%↓

ABT

109.53

+0.63%↑

RDY

13.98

+1.3%↑

NEOG

10.33

+0.68%↑

JNJ

235.52

+0.87%↑

ISRG

477.08

-0.52%↓

ABT

109.53

+0.63%↑

RDY

13.98

+1.3%↑

NEOG

10.33

+0.68%↑

JNJ

235.52

+0.87%↑

ISRG

477.08

-0.52%↓

ABT

109.53

+0.63%↑

RDY

13.98

+1.3%↑

NEOG

10.33

+0.68%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.1 -3.51

Buy Sell

Overview

Share price change

24h

Current

Min

1.1

Max

1.16

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+296.75% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	16M 142M
Previous open	4.61
Previous close	1.1

News Sentiment

By Acuity

34%

66%

95 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 23:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 lut 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 lut 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 lut 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 lut 2026, 23:38 UTC

Earnings

AMD Sales Climb on Help From Data-Center Business -- Update

3 lut 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 lut 2026, 23:27 UTC

Acquisitions, Mergers, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 lut 2026, 23:25 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 lut 2026, 23:22 UTC

Acquisitions, Mergers, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 lut 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 lut 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 lut 2026, 22:56 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 lut 2026, 22:40 UTC

Earnings

Amdocs Extends Collaboration With T-Mobile

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Adj EPS $1.81

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q Rev $1.16B

3 lut 2026, 22:39 UTC

Earnings

Amdocs 1Q EPS $1.45 >

3 lut 2026, 22:38 UTC

Earnings

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 lut 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 lut 2026, 22:14 UTC

Earnings

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 lut 2026, 22:13 UTC

Earnings

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 lut 2026, 22:12 UTC

Earnings

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 lut 2026, 22:10 UTC

Earnings

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 lut 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 lut 2026, 22:10 UTC

Earnings

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 lut 2026, 22:09 UTC

Earnings

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

296.75% upside

12 Months Forecast

Average 4.88 USD 296.75%

High 8 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

95 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.